Oxford Nanopore Technologies is set to partner with Geneyx for the development of a scalable software solution for use in nanopore sequencing.

The new software solution is being developed for the end-to-end analysis and clinical reporting of nanopore sequencing data.

Hospitals, genetic labs and researchers can use the new advanced platform to collect data and analyse human whole-genome sequencing.

Expected to be available after the completion of a pilot phase, the new software platform will mainly focus on accelerating the clinical use of nanopore sequencing besides loading, visualising and interpreting nanopore sequencing data.

The platform will be initially used for newborn screening, as well as the research and characterisation of rare and undiagnosed diseases.

According to Oxford Nanopore, the software is anticipated to offer a “one-click” analysis of whole human sequencing data, including useful genetic variants.   

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Oxford Nanopore CEO Gordon Sanghera said: “We are excited to collaborate with Geneyx to develop an end-to-end analysis tool for the clinical reporting of nanopore sequencing data.”

Under the collaboration, Geneyx’s data analysis capabilities will be combined with Oxford Nanopore’s human-variation workflow and secure data transfer.

The platform will be integrated with Oxford Nanopore’s data analysis solution, EPI2ME, to conduct the secondary sequence analysis.

The results will then be sent to the Geneyx cloud and on-site capability for accurate annotation and variants classification. It will help offer simplified bioinformatics for future clinical applications.

The partnership will begin with pilot projects to assess the platform within third-party sites. At present, the Geneyx solution is used by 4,000 active users in 36 countries across the world.

Geneyx CEO David Yizhar said: “This collaboration combines Geneyx’s analysis expertise with Oxford Nanopore Technologies’ groundbreaking sequencing technology.”